Physician profile
Charisma James
NPI 1063148625
$410.46
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $176.82 | 2023-2024 | Gemtesa, Myfembree |
| Evofem Biosciences, INC. | $63.21 | 2023-2024 | Phexxi |
| Organon LLC | $41.69 | 2023-2024 | Nexplanon |
| Daiichi Sankyo INC. | $26.10 | 2024 | Injectafer |
| Janssen Biotech, INC. | $23.30 | 2023 | Erleada |
| Boston Scientific Corporation | $21.25 | 2023 | Varithena Administration Pack |
| Agile Therapeutics, INC. | $21.02 | 2024 | Twirla |
| Abbvie INC. | $20.63 | 2023 | |
| Hologic Sales and Service, LLC | $16.44 | 2024 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisma James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.